

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:  
Andreas Meinke et al.

Serial No.: 10/556,060

Filed: November 7, 2005

For: S. AGALACTIAE ANTIGENS I + II

Group Art Unit: 1645

Examiner: Baskar, Padmavathi

Atty. Dkt. No.: SONN:080US

Confirmation No.: 5339

**CERTIFICATE OF ELECTRONIC SUBMISSION**

DATE OF SUBMISSION: November 8, 2006

**INFORMATION DISCLOSURE STATEMENT**

**MS AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. § 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. § 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/SONN:080US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Mark B. Wilson  
Reg. No. 37,259  
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201

Date: November 8, 2006

Form PTO-1449 (modified)

Atty. Docket No.

SONN:080US

Serial No.

10/556,060

List of Patents and Publications for Applicant's

Applicant

Andreas Meinke *et al.*

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

November 7, 2005

Group:

1645

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language
	B1	WO 02/059148	08/01/02	WIPO	English

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Brodeur <i>et al.</i> , "Identification of group B streptococcal Sip protein, which elicits cross-protective immunity," <i>Infection and Immunity</i> , 68:5610-5618, 2000.
	C2	Database EMBL accession number: AE014198.
	C3	Database EMBL accession number: AL766844.
	C4	Etz <i>et al.</i> , "Identification of in vivo expressed vaccine candidate antigens from <i>Staphylococcus aureus</i> ," <i>Proc. Natl. Acad. Sci. USA</i> , 99:6573-6578, 2002.
	C5	Glaser <i>et al.</i> , "Genome sequence of <i>Streptococcus agalactiae</i> , a pathogen causing invasive neonatal disease," <i>Molecular Microbiology</i> , 45:1499-1513, 2002.
	C6	Henics <i>et al.</i> , "Small-fragment genomic libraries for the display of putative epitopes from clinically significant pathogens," <i>Biotechniques</i> , 35:196-200, 202, 20, 2003.
	C7	Hughes <i>et al.</i> , "Novel protein vaccine candidates against Group B streptococcal infection identified using alkaline phosphate fusions," <i>FEMS Microbiology Letters</i> , 222:263-271, 2003.
	C8	Klade, "Proteomics approaches towards antigen discovery in vaccine development," <i>Current Opinion in Molecular Therapeutics</i> , 4:216-224, 2002.
	C9	Larsson <i>et al.</i> , "Protection against experimental infection with group B streptococcus by immunization with a bivalent protein vaccine," <i>Vaccine</i> , 17:454-458, 1999.
	C10	Michel <i>et al.</i> , "Cloned alpha and beta C-protein antigens of group B Streptococci elicit protective immunity," <i>Infection and Immunity</i> , 59:2023-2028, 1991.

25710436.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No. SONN:030US	Serial No. 10/556,060
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant Andreas Meinke <i>et al.</i>	
		Filing Date: November 7, 2005	Group: 1645
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C11	Moyo <i>et al.</i> , "The putative R1 protein of streptococcus agalactiae as serotype marker and target of protective antibodies," <i>APMIS</i> , 109:842-848, 2001.
	C12	Tettelin <i>et al.</i> , "Complete genome sequence and comparative genomic analysis of an emerging human pathogen, serotype V <i>Streptococcus agalactiae</i> ," <i>Proc. Natl. Acad. Sci. USA</i> , 99:12391-12396, 2002.

25710436.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.